108 related articles for article (PubMed ID: 22093205)
1. Safety and efficacy of adjusted-dose eptifibatide in patients with acute coronary syndromes and reduced renal function.
Melloni C; James SK; White JA; Giugliano RP; Harrington RA; Huber K; Tricoci P; Armstrong PW; Van de Werf F; Montalescot G; Califf RM; Newby LK
Am Heart J; 2011 Nov; 162(5):884-892.e1. PubMed ID: 22093205
[TBL] [Abstract][Full Text] [Related]
2. Early versus delayed, provisional eptifibatide in acute coronary syndromes.
Giugliano RP; White JA; Bode C; Armstrong PW; Montalescot G; Lewis BS; van 't Hof A; Berdan LG; Lee KL; Strony JT; Hildemann S; Veltri E; Van de Werf F; Braunwald E; Harrington RA; Califf RM; Newby LK;
N Engl J Med; 2009 May; 360(21):2176-90. PubMed ID: 19332455
[TBL] [Abstract][Full Text] [Related]
3. Upstream clopidogrel use and the efficacy and safety of early eptifibatide treatment in patients with acute coronary syndrome: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) trial.
Wang TY; White JA; Tricoci P; Giugliano RP; Zeymer U; Harrington RA; Montalescot G; James SK; Van de Werf F; Armstrong PW; Braunwald E; Califf RM; Newby LK
Circulation; 2011 Feb; 123(7):722-30. PubMed ID: 21300952
[TBL] [Abstract][Full Text] [Related]
4. Sex differences in major bleeding with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) initiative.
Alexander KP; Chen AY; Newby LK; Schwartz JB; Redberg RF; Hochman JS; Roe MT; Gibler WB; Ohman EM; Peterson ED;
Circulation; 2006 Sep; 114(13):1380-7. PubMed ID: 16982940
[TBL] [Abstract][Full Text] [Related]
5. Upstream use of small-molecule glycoprotein iib/iiia inhibitors in patients with non-ST-segment elevation acute coronary syndromes: a systematic overview of randomized clinical trials.
Tricoci P; Newby LK; Hasselblad V; Kong DF; Giugliano RP; White HD; Théroux P; Stone GW; Moliterno DJ; Van de Werf F; Armstrong PW; Prabhakaran D; Rasoul S; Bolognese L; Durand E; Braunwald E; Califf RM; Harrington RA
Circ Cardiovasc Qual Outcomes; 2011 Jul; 4(4):448-58. PubMed ID: 21712522
[TBL] [Abstract][Full Text] [Related]
6. Age, treatment, and outcomes in high-risk non-ST-segment elevation acute coronary syndrome patients: insights from the EARLY ACS trial.
Lopes RD; White JA; Tricoci P; White HD; Armstrong PW; Braunwald E; Giugliano RP; Harrington RA; Lewis BS; Brogan GX; Gibson CM; Califf RM; Newby LK
Int J Cardiol; 2013 Sep; 167(6):2580-7. PubMed ID: 22795720
[TBL] [Abstract][Full Text] [Related]
7. Routine early eptifibatide versus delayed provisional use at percutaneous coronary intervention in high-risk non-ST-segment elevation acute coronary syndromes patients: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome trial.
Bagai A; White JA; Lokhnygina Y; Giugliano RP; Van de Werf F; Montalescot G; Armstrong PW; Tricoci P; Gibson CM; Califf RM; Harrington RA; Newby LK
Am Heart J; 2013 Sep; 166(3):466-73. PubMed ID: 24016495
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic and pharmacodynamic properties of eptifibatide in subjects with normal or impaired renal function.
Gretler DD; Guerciolini R; Williams PJ
Clin Ther; 2004 Mar; 26(3):390-8. PubMed ID: 15110131
[TBL] [Abstract][Full Text] [Related]
9. Adjusting eptifibatide doses for renal impairment: a model of dosing agreement among various methods of estimating creatinine clearance.
Healy MF; Speroni KG; Eugenio KR; Murphy PM
Ann Pharmacother; 2012 Apr; 46(4):477-83. PubMed ID: 22474135
[TBL] [Abstract][Full Text] [Related]
10. Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial).
Cornel JH; Tricoci P; Lokhnygina Y; Moliterno DJ; Wallentin L; Armstrong PW; Aylward PE; Clare RM; Chen E; Leonardi S; Van de Werf F; White HD; Held C; Strony J; Mahaffey KW; Harrington RA
Am J Cardiol; 2015 May; 115(10):1325-32. PubMed ID: 25776457
[TBL] [Abstract][Full Text] [Related]
11. The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: the do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial.
Berger PB; Best PJ; Topol EJ; White J; DiBattiste PM; Chan AW; Kristensen SD; Herrmann HC; Moliterno DJ
Am Heart J; 2005 May; 149(5):869-75. PubMed ID: 15894970
[TBL] [Abstract][Full Text] [Related]
12. Anticoagulation with otamixaban and ischemic events in non-ST-segment elevation acute coronary syndromes: the TAO randomized clinical trial.
Steg PG; Mehta SR; Pollack CV; Bode C; Cohen M; French WJ; Hoekstra J; Rao SV; Ruzyllo W; Ruiz-Nodar JM; Sabaté M; Widimsky P; Kiss RG; Navarro Estrada JL; Hod H; Kerkar P; Guneri S; Sezer M; Ruda M; Nicolau JC; Cavallini C; Ebrahim I; Petrov I; Kim JH; Jeong MH; Ramos Lopez GA; Laanmets P; Kovar F; Gaudin C; Fanouillere KC; Minini P; Hoffman EB; Moryusef A; Wiviott SD; Sabatine MS;
JAMA; 2013 Sep; 310(11):1145-55. PubMed ID: 23995608
[TBL] [Abstract][Full Text] [Related]
13. Glycoprotein IIb/IIIa inhibitors in patients with renal insufficiency undergoing percutaneous coronary intervention.
Anderson JR; Riding D
Cardiol Rev; 2008; 16(4):213-8. PubMed ID: 18562812
[TBL] [Abstract][Full Text] [Related]
14. The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome--study design and rationale.
Giugliano RP; Newby LK; Harrington RA; Gibson CM; Van de Werf F; Armstrong P; Montalescot G; Gilbert J; Strony JT; Califf RM; Braunwald E;
Am Heart J; 2005 Jun; 149(6):994-1002. PubMed ID: 15976780
[TBL] [Abstract][Full Text] [Related]
15. Fasting glucose, NT-proBNP, treatment with eptifibatide, and outcomes in non-ST-segment elevation acute coronary syndromes: An analysis from EARLY ACS.
Farhan S; Clare RM; Jarai R; Giugliano RP; Lokhnygina Y; Harrington RA; Kristin Newby L; Huber K
Int J Cardiol; 2017 Apr; 232():264-270. PubMed ID: 28089149
[TBL] [Abstract][Full Text] [Related]
16. Practice patterns and clinical outcomes among non-ST-segment elevation acute coronary syndrome (NSTE-ACS) patients presenting to primary and tertiary hospitals: insights from the EARLY glycoprotein IIb/IIIa inhibition in NSTE-ACS (EARLY-ACS) trial.
Toleva O; Westerhout CM; Senaratne MP; Bode C; Lindroos M; Sulimov VA; Montalescot G; Newby LK; Giugliano RP; Van de Werf F; Armstrong PW
Catheter Cardiovasc Interv; 2014 Nov; 84(6):934-42. PubMed ID: 24976083
[TBL] [Abstract][Full Text] [Related]
17. Design and rationale of the treatment of acute coronary syndromes with otamixaban trial: a double-blind triple-dummy 2-stage randomized trial comparing otamixaban to unfractionated heparin and eptifibatide in non-ST-segment elevation acute coronary syndromes with a planned early invasive strategy.
Steg PG; Mehta SR; Pollack CV; Bode C; Gaudin C; Fanouillere K; Moryusef A; Wiviott SD; Sabatine MS
Am Heart J; 2012 Dec; 164(6):817-24.e13. PubMed ID: 23194481
[TBL] [Abstract][Full Text] [Related]
18. Duration of eptifibatide infusion after percutaneous coronary intervention and outcomes among high-risk patients with non-ST-segment elevation acute coronary syndrome: insights from EARLY ACS.
Hess CN; Schulte PJ; Newby LK; Steg PG; Dalby AJ; Schweiger MJ; Lewis BS; Armstrong PW; Califf RM; van de Werf F; Harrington RA
Eur Heart J Acute Cardiovasc Care; 2013 Sep; 2(3):246-55. PubMed ID: 24222836
[TBL] [Abstract][Full Text] [Related]
19. [The clinical use of the GPIIb/IIIa inhibitors eptifibatide and tirofiban in the treatment of acute coronary syndromes of the "non-ST elevation" type].
Galli M; Maggioni AP; Vassanelli C; Tavazzi L
Ital Heart J Suppl; 2000 Feb; 1(2):202-11. PubMed ID: 10731377
[TBL] [Abstract][Full Text] [Related]
20. Angiographic outcomes with early eptifibatide therapy in non-ST-segment elevation acute coronary syndrome (from the EARLY ACS Trial).
Kunadian V; Giugliano RP; Newby LK; Zorkun C; Guo J; Bagai A; Montalescot G; Braunwald E; Califf RM; Van de Werf F; Armstrong PW; Harrington R; Gibson CM
Am J Cardiol; 2014 Apr; 113(8):1297-305. PubMed ID: 24607027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
